v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Net income (loss) $ (1,747) $ (8,843)
Depreciation 2,912 2,663
Amortization of acquisition related intangible assets 0 345
Non-cash operating lease cost 929 1,067
Stock-based compensation expense 8,474 5,411
Deferred income taxes 237 15
Provision for credit losses (97) 133
Provision for inventory 2,575 3,842
Interest income on notes receivable (354) (345)
Gain on sale of assets (84) (505)
Changes in operating assets and liabilities:    
Accounts receivable (5,408) 659
Inventories (11,420) 2,252
Prepaid expenses, other current and long-term assets (831) 797
Accounts payable 170 (1,066)
Operating lease liabilities (937) (1,045)
Accrued expenses, other current and long-term liabilities (1,074) (5,251)
Income taxes 1,125 (448)
Net cash used in operating activities (5,530) (319)
Cash flows from investing activities:    
Proceeds from sale of Parcus Medical, net 0 4,496
Proceeds from sale of intangible assets 0 600
Notes receivable 361 328
Purchases of property and equipment (2,880) (4,291)
Net cash used in by investing activities (2,519) 1,133
Cash flows from financing activities:    
Proceeds from employee stock purchase program 198 261
Cash paid for tax withheld on vested restricted stock awards (1,715) (1,549)
Proceeds from exercises of equity awards 12 0
Repurchases of common stock (9,543) (3,971)
Net cash used in financing activities (11,048) (5,259)
Exchange rate impact on cash    
Exchange rate impact on cash 28 453
Decrease in cash and cash equivalents (19,069) (3,992)
Cash and cash equivalents at beginning of period 57,481 57,159
Cash and cash equivalents at end of period 38,412 53,167
Non-cash investing activities:    
Purchases of property and equipment included in accounts payable and accrued expenses $ 496 $ 820